Blog Posts

Françoise Meunier: The Launch of the First National Cancer Mission Hub in Poland

Françoise Meunier/LinkedIn

May 23, 2025, 12:12

Françoise Meunier: The Launch of the First National Cancer Mission Hub in Poland

Françoise Meunier, Founder of the European Initiative on Ending Discrimination Against Cancer Survivors, shared a post on LinkedIn:

“It was an absolute pleasure to participate in the Cancer Mission Fair in Warsaw, which marked the launch of the first National Cancer Mission Hub in Poland.

This unique event brought together citizens, policymakers, researchers, and innovators from across Europe — all committed to transforming cancer care and research. It’s truly encouraging to see such collective energy not just in words, but in action.

I had the opportunity to join numerous sessions to speak about the importance of ending discrimination against cancer survivors. The readiness of everyone participating to advance the topic of the right to be forgotten was incredibly inspiring. The last two days were filled with great sessions and engaging discussions with many people from different countries.

Congratulations to ECHoS | Establishing of Cancer Mission Hubs: Networks and Synergies and the Maria Sklodowska-Curie National Research Institute of Oncology for the stellar organisation of the event. We will not stop working to end discrimination against cancer survivors.”

More posts featuring Françoise Meunier.

cancer Cancer Mission Fair cancer survivors Curie National Research Institute of Oncology ECHoS Ending Discrimination Against Cancer Survivors Establishing of Cancer Mission Hubs fight against cancer Françoise Meunier Global fight against cancer Maria Sklodowska National Cancer Mission Hub OncoDaily Oncology Poland Warsaw

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC